Voydeya
What Voydeya is used for
Voydeya is indicated as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
- PRIME: a priority medicine that the EMA supported early because it may meet an unmet need.
Key facts
- Brand
- Voydeya
- Active substance
- danicopan
- Disease area
- Hemoglobinuria, Paroxysmal; Hemolysis
- Medicine group
- Immunosuppressants, Complement inhibitors
- ATC code
- L04AJ09
- Marketing authorisation holder
- Alexion Europe SAS
- Authorised in the EU since
- 2024
Official information
In the USA
Same active substance: Voydeya
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Voydeya used for?
Voydeya is indicated as an add-on to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have residual haemolytic anaemia
What is the active substance in Voydeya?
Voydeya contains danicopan.
Who makes Voydeya?
The EU marketing authorisation holder is Alexion Europe SAS.
Is Voydeya an orphan medicine?
Yes. Voydeya is designated an orphan medicine in the EU, for a rare disease (Hemoglobinuria, Paroxysmal; Hemolysis).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU